Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Market Movers Today: Facebook, Inc. (FB), Geron Corporation (GERN), Heron Therapeutics Inc (HRTX), Micro Focus International PLC – ADR (MFGP), and More

Page 1 of 2

Facebook, Inc. (NASDAQ:FB) (Los Angeles Times)
Facebook Inc.’s stock tumbled Monday after the social media company accused a data analytics firm used by the Trump campaign of exploiting ill-gotten data belonging to unwitting Facebook users. Shares of Facebook sank 6.7% to $172.69 around 9:50 a.m. Pacific time. On Friday, a Facebook executive said in a blog post that the Menlo Park, Calif., company was suspending data analytics firm Strategic Communication Laboratories and its affiliate Cambridge Analytica. Facebook said the two companies had failed to delete user data it had acquired in 2015 in violation of the platform’s rules.

Geron Corporation (NASDAQ:GERN) (The Motley Fool)
What happened: Shares of Geron Corporation (NASDAQ:GERN), a clinical-stage biotech developing a cancer therapy, popped this morning after the company included a pipeline update with its fourth-quarter earnings report after Friday’s bell. The improved outlook for imetelstat has pushed the stock 28.8% higher as of 11:29 a.m. EDT on Monday.

stocks, analysis, market, numbers, business, ticker, trade, money, price, investment, index, chart

crystal51/Shutterstock.com

Heron Therapeutics Inc (NASDAQ:HRTX) (MarketWatch)
Heron Therapeutics Inc.’s shares HRTX, +26.98% surged 28% in premarket trade Monday, after the company announced positive results in a late-stage trial of an anesthetic used for patients undergoing bunionectomy and hernia repair. The company said the trial of its HTX-011 agent showing significant reductions in pain intensity and use of opioids afterachieved all primary and key secondary endpoints in two Phase 3 trials, surgery.

Micro Focus International PLC – ADR (NYSE:MFGP) (The Wall Street Journal)
LONDON—Micro Focus International PLC’s $8.8 billion merger with Hewlett Packard Enterprise Co.’s software business represented a rarity 18 months ago: a British tech company taking over a foreign one, rather than the other way around. It hasn’t worked out as planned. Micro Focus shares fell by as much as 55% Monday, wiping about £4.5 billion ($6.3 billion) off its market value, after it said technical problems related to combining the computer systems of Micro Focus and HPE would lead to lower-than-expected sales.

Page 1 of 2
Loading...